Johnson and Johnson JNJ

Johnson & Johnson is actively pursuing a $20 billion sale of its orthopedics business to streamline operations and focus on higher growth areas. This decision follows a solid Q1 2026 report, with revenues reaching $24.06 billion despite facing over 73,000 lawsuits related to its talc products. J&J's stock has increased 38.4% over six months, signaling strong market performance, although the company still navigates significant legal challenges. With a projected growth in its Innovative Medicine sector, J&J aims to bolster its financial standing while adjusting its business strategy to prioritize more lucrative divisions.